Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy
article
OA: closed
CC0
⤵ 5 in-corpus citations
AI-generated summary
This study evaluated an extended-cycle oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest, assessing its impact on bleeding patterns, safety, patient acceptance, and contraceptive effectiveness.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BackgroundThe present study compared the efficacy and safety of a combined oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest (EE/DNG) in conventional and extended-cycle regimen over 1 year of treatment.Study designIn a phase III, randomized, prospective, open, two-arm, multicenter study, 1315 sexually active women (range, 18-40 years) were treated with EE/DNG either conventionally (21/7 days) or according to an extended-cycle regimen (84/7 days). Data were documented on volunteer diaries, and adverse events (AEs) were reported during five visits.ResultsIn the extended-regimen group, the total number of days with bleeding progressively decreased over time, and overall, the volunteers had fewer numbers of days with bleeding/spotting compared to those treated conventionally. Intracyclic bleeding, on the other hand, was more frequent in the extended-cycle group, although its frequency considerably decreased over time. Both regimens offered reliable contraception, with an unadjusted Pearl Index of 0.489 for the conventional regimen and 0.495 for the extended regimen. The number of AEs was higher in the extended-cycle group, although the group differences tended to decrease over time.ConclusionsExtended-cycle use of EE/DNG was effective and mostly well tolerated, appearing to be a favorable option for women who need or wish to omit the pill-free interval.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters 2008
- Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use 2009
- Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use 2008
- Extended and Continuous Use of Hormonal Contraceptives to Reduce Menstruation 2006
Cited by (3)
- Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive 2016
- Continuous use of oral contraceptives: an overview of effects and side‐effects 2012
- Prise en charge des ménorragies : recommandations pour la pratique clinique du Collège national des gynécologues et obstétriciens français (CNGOF) 2022
References (49)
- Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use via openalex
- Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use via openalex
- Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters via openalex
- Extended and Continuous Use of Hormonal Contraceptives to Reduce Menstruation via openalex
- doi:10.1016/0010-7824(96)00137-0 via openalex
- doi:10.1016/j.contraception.2007.01.014 via openalex
- doi:10.1067/mob.2002.122988 via openalex
- doi:10.1016/j.contraception.2006.10.009 via openalex
- W81673947 via openalex
- doi:10.1016/s0002-9378(98)70047-x via openalex
- doi:10.1016/j.ajog.2006.05.012 via openalex
- doi:10.1016/j.contraception.2005.06.068 via openalex
- doi:10.1016/0002-9378(90)90560-t via openalex
- doi:10.1016/s0015-0282(99)00205-8 via openalex
- doi:10.1055/s-0030-1248263 via openalex
- doi:10.1016/j.contraception.2006.02.006 via openalex
- doi:10.1016/s0010-7824(99)00043-8 via openalex
- doi:10.1136/bmj.b2890 via openalex
- doi:10.1111/j.1526-4610.2007.00650.x via openalex
- doi:10.1016/j.contraception.2006.07.009 via openalex
- doi:10.1016/s0029-7844(96)00488-7 via openalex
- doi:10.1016/j.ajog.2004.02.012 via openalex
- doi:10.2165/00003495-200464210-00006 via openalex
- doi:10.1097/01.aog.0000175144.08035.74 via openalex
- doi:10.1016/j.contraception.2007.02.005 via openalex
- doi:10.1016/s0029-7844(03)00014-0 via openalex
- doi:10.1016/j.contraception.2009.07.003 via openalex
- W4285719527 via openalex
- W6603199455 via openalex
- doi:10.1080/13625180701441121 via openalex
- doi:10.1016/s0029-7844(99)00524-4 via openalex
- doi:10.1016/j.contraception.2005.09.009 via openalex
- doi:10.1016/j.contraception.2007.05.081 via openalex
- doi:10.1016/s0140-6736(05)79442-3 via openalex
- doi:10.1097/aog.0b013e3181842071 via openalex
- doi:10.1016/s0010-7824(03)00141-0 via openalex
- doi:10.1093/humrep/dei377 via openalex
- doi:10.1016/j.contraception.2006.03.022 via openalex
- doi:10.1097/01.aog.0000199950.64545.16 via openalex
- doi:10.1016/j.contraception.2004.07.013 via openalex
- doi:10.1016/j.contraception.2004.02.010 via openalex
- doi:10.1016/j.ajog.2005.12.045 via openalex
- doi:10.1016/j.contraception.2006.05.050 via openalex
- doi:10.1160/th04-11-0759 via openalex
- doi:10.1016/j.contraception.2005.09.010 via openalex
- doi:10.1016/j.whi.2004.08.005 via openalex
- doi:10.1016/j.contraception.2006.07.005 via openalex
- doi:10.1016/j.ajog.2006.02.048 via openalex
- doi:10.1016/j.contraception.2009.05.004 via openalex
Cited by (3)
- Prise en charge des ménorragies : recommandations pour la pratique clinique du Collège national des gynécologues et obstétriciens français (CNGOF) 2022
- Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive 2016
- Continuous use of oral contraceptives: an overview of effects and side‐effects 2012
Source provenance
- openalex
- last seen: 2026-05-11T06:39:27.580236+00:00
License: CC0
· commercial use OK